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Available online 28 June 2017This review gives an updated overview on keratinocyte transplantation in burn wounds concentrating on appli-
cationmethods and future therapeutic cell delivery optionswith a special interest in hydrogels and spray devices
for cell delivery.
To achieve faster re-epithelialisation of burnwounds, the original autologous keratinocyte culture and transplan-
tation technique was introduced over 3 decades ago. Application types of keratinocytes transplantation have im-
proved from cell sheets to single-cell solutions delivered with a spray system. However, further enhancement of
cell culture, cell viability and function in vivo, cell carrier and cell delivery systems remain themes of interest.
Hydrogels such as chitosan, alginate, ﬁbrin and collagen are frequently used in burnwound care and have advan-
tageous characteristics as cell carriers.
Future approaches of keratinocyte transplantation involve spray devices, but optimisation of application tech-
nique and carrier type is necessary..
.V. This is an© 2017 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license
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Burn injuries are complicated wounds to manage with a relative
high mortality rate in especially large area burns and elderly patients
[1]. Substantial tissue damage and extensive ﬂuid loss can cause
impaired vital functions of the skin. Rapid epithelialisation ismandatory
to restore the barrier function of the skin and enhance healing. Patho-
logical scar formation (hypertrophic scarring) can occur as a long
term sequelae of delayed wound healing. When healing is delayed,
the potential short term common complications include wound infec-
tion affecting the local healing process or systemic inﬂammatory and
immunological responses which subsequently can cause life threaten-
ing sepsis and multi-organ failure. In the United states, approximately
400,000 ﬁre/burn injuries were recorded in 2014 in a population of
about 300 million, including a total of 3196 (0.78%) fatal injuries (data
from CDC in WISQARS Injury Mortality Report) [2].
Fortunately, survival rates have improved drastically over the last
century due to advancements in burn care such as early surgical inter-
vention, critical care support and wound care [3,4]. However, despite
further technological advancements in the last 30 years, survival rates
have not improved signiﬁcantly over the last three decades and now
seem to be plateauing in countries with high-standard burn care [5–7].
Furthermore, since modern standard burn care allows the majority
of patients to survive thermal injury, other outcome measurements
aiming to improve quality of life become more relevant. For example,
shortening length of hospital stay, decreasing the number of trips to
the operating theatre and optimizing the quality of restored tissue.
Functional and aesthetic outcome of the restored tissue are reﬂected
by scar quality in terms of pigmentation, pliability, sensation, hair
growth and function (prevention of scar contraction).
All of these factors require a specialized approach aiming on regen-
eration of tissue instead of tissue repair. Progress in short term results
(lifesavingwound coverage) remains essential. Subsequently, advances
of long term results are desired to facilitate the need for quality of life
improvement of the increasing population of burn survivors. Answers
to these challenges are sought in the ﬁeld of tissue engineering. Al-
though, advances in engineered skin equivalents and cell-delivery to
the wound bed are emerging in burn care, they currently do not meet
the expected results and translation to clinical practice is challenging.
Keratinocyte delivery was the ﬁrst skin cell transplantation successfully
translated to the clinical burn care. In the last four decades this method
has been investigated widely and numerous researchers have contrib-
uted to a variety of improvements. This review gives an updated over-
view on applications of keratinocyte delivery in burns and wound
healing and future therapeutic cell delivery optionswith a special inter-
est in hydrogels and spray devices for cell delivery.2. Skin
2.1. Epidermis
The skin is the largest organ of the body and has a barrier function,
preventing the passage of water, electrolytes and pathogens (Fig. 1).
The epidermis is predominantly formed from highly specialized epithe-
lial cells called keratinocytes. Other cells which can be found in the epi-
dermis include Langerhans' cells, melanocytes and Merkel cells, which
are responsible for immune regulation, pigmentation and sensory func-
tion. Keratinocytes play a key role in epidermal restoration following
injury through proliferation and re-epithelialisation (Fig. 2). Solely epi-
dermal injuries will achieve re-epithelialisation from proliferated
keratinocytes and heal by regeneration without scarring [8,9]. Differen-
tiated keratinocytes perform their barrier function through the provi-
sion of a mechanical barrier in the formation of a keratinised layer and
by reacting to invasion of pathogens via release of pro-inﬂammatory
mediators which subsequently attract leukocytes to the site of invasion.
2.1.1. Keratinocyte differentiation and proliferation markers
Keratinocytes proliferate from the basal cells of the innermost
layer of the skin (stratum basale). The epidermal stem cells are at-
tached by hemi-desmosomes to the stratum basale and can divide
into either more stem cells, which persist indeﬁnitely and to maintain
the layer's regenerative capacity, or into transit amplifying cells which
have limited division potential. As the transit amplifying cells continue
to divide and proliferate, differentiation occurs. Throughout this differen-
tiation process, the keratinocytes migrate upwards towards the stratum
spinosum and stratum granulosum to eventually become corneocytes
which form a relatively impermeable outer layer, the stratum corneum.
Once fully differentiated, these corneocytes lose their nucleus and cyto-
plasmic organelles and will eventually be shed off via desquamation.
The estimated time for turnover from epidermal stem cell to desquama-
tion in healthy human skin is around 39 days [10].
During this process, keratinocytes express several differentiation
proteins including keratins which are intermediate ﬁlament proteins
in epithelial cells. Keratins play a host of important function including
the provision of structural support, protection of epithelial cells from
mechanical and non-mechanical stress and the regulation of apoptosis
and protein synthesis [11]. There are 37 known functional human epi-
thelial keratin genes, divided in type 1 and 2 genes. Mutations in these
genes are associated with skin diseases such as epidermolysis bullosa
simplex (keratin 5, 14) with structural weak epidermal basal cells or
epidermolytic hyperkeratosis (keratin 1 and 10) [12]. Keratin expres-
sion is frequently used as a marker for epidermal proliferation and dif-
ferentiation in cell culture, with keratin 14 (K14) being used for the
Fig. 1. Layers and function of the skin. The uppermost layer of the skin is the epidermis. The epidermis consists of 5main layers described fromdeep to superﬁcial: stratumbasale, stratum
spinosum, stratum granulosum, stratum lucidum and stratum corneum. The epidermis has two distinct functions: a protective barrier function against trauma and ﬁghting off pathogens
as well as a controlling function regulating body temperature, ﬂuid and electrolyte balance. Other functions of the epidermis include production of vitamin D, pigmentation, providing
mechanical strength and it has a role in cutaneous immune function.
[Source: histology image provided by Dr. GM Reynolds PhD CSci FIBMS, Liver Unit of Queen Elizabeth Hospital Birmingham, UK. Image adapted by Britt ter Horst, with permission from G
M Reynolds.]
20 B. ter Horst et al. / Advanced Drug Delivery Reviews 123 (2018) 18–32basal layer and keratin 10 for the spinous layer. Other differentiation
markers starting at the basal layer are K5, and K15, spinous layers K1
and K10, transglutaminase and involucrin, at the granular layer.
Filagrine, loricrin and caspase-14 activation are hypothesised to play a
role in terminal keratinocyte differentiation [13–15]. (Fig. 2).2.1.2. Factors promoting keratinocyte differentiation
Amajor regulator of keratinocyte differentiation is the calcium gra-
dient. Extracellular calcium concentration is lowest in the stratum
basale and gradually increases until the stratum granulosum. Elevated
levels of extracellular calcium concentrations stimulate formation of
intercellular contacts and the increase of intracellular free calcium con-
centrations via transmembrane calcium inﬂux, which subsequently
initiates differentiation via stimulation of the calcium receptor (CaR)
[14]. This has consequences for the culture technique of keratinocytes
in vivo, high calcium concentration induces differentiation, whereas
in low calcium concentration keratinocytes remain proliferative [14–
16].
E-cadherin provides adherens junctions for adhesion between cells
which is crucial for keratinocyte differentiation. In addition, following
a signalling pathway e-cadherin can increase the intracellular calcium
concentration [14]. Furthermore, 1,25-Dihydroxyvitamin D3 (Vitamin
D3) is known to inﬂuence keratinocyte differentiation by regulating
gene expression and modulating calcium concentrations [17,18].
Logically, factors that promote proliferation will inhibit differen-
tiation of keratinocytes. Factors known to promote proliferation are
TGF-α, vitamin A, transcription factor p63 and epidermal growth
factor (EGF).2.1.3. Keratinocyte interaction with other epidermal cells
Within the epidermis, keratinocytes interact with other surrounding
cell types for example, melanocytes. Melanin production (melanogene-
sis), occurs in the melanocytes and protects the DNA of melanocytes
and keratinocytes from ultraviolet radiation and contributes to the
colouration of the skin. Keratinocytes take up melanin via the melanin
containing melanosomes produced by melanocytes [19].
The interactions between keratinocytes and ﬁbroblasts in wound
healing have been well described in literature, where a double para-
crine signalling concept is proposed. Keratinocytes instruct ﬁbro-
blasts to produce growth factors and cytokines such as keratinocyte
growth factor, ﬁbroblast growth factor-7, GM-CSF and IL-6 [20]. Con-
sequently, expression of these growth factors initiates keratinocyte
proliferation. The transcription factor activator protein-1 seems to
play an important role in this process [21]. Furthermore, under the
control of keratinocytes, ﬁbroblasts can obtain a myoﬁbroblast phe-
notype, which is important for wound contraction [20].2.2. Dermis and basement membrane
Underneath the epidermis, the dermal layer acts a support net-
work, providing strength and elasticity to the skin. Fibroblasts are
the key cells of the dermis. Fibroblasts are responsible for the pro-
duction andmaintenance of the extracellular matrix which is formed
by ﬁbrous components (collagen and elastin) embedded in non-ﬁ-
brous elements such as proteoglycans and glycosaminoglycans
(GAGs). Collagens are the main structural element of the extracellular
matrix (ECM) and provide tensile strength, regulate cell adhesion and
Fig. 2.Keratinocyte differentiation andmarkers. Diagram is showing differentiation of keratinocytes in the epidermiswith expression of stratiﬁcationmarkers. Basal keratinocytes express
Keratin 5, keratin 14 and keratin 15.When keratinocytes differentiate theymove upwards into the suprabasal layers: stratumspinosum, stratumgranulosumand ﬁnally stratumcorneum.
Differentiating keratinocytes express speciﬁc markers in each epidermal layer.
[Source: Britt ter Horst].
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smoothmuscle cells andmast cells [22]. The vascular deep and superﬁ-
cial plexus lie within the upper and lower part of the reticular dermis
respectively and supply the dermis and epidermis. The epidermis and
dermis are ﬁrmly connected by the basement membrane, and the epi-
dermal-dermal junction is bordered and stabilized by the anchoring of
keratinocyte-derived collagen (type VII) ﬁbrils into the dermis. Addi-
tionally, collagen XVII, a structural component of hemidesmosomes,
mediates the anchoring of basal epithelial cells to the basement mem-
brane [23]. If this junction is disrupted, serious morbidity such as seen
in epidermolysis bullosa can occur [12].
Several structures originate in the dermis and extend into the epi-
dermis such as sensory nerves, sweat glands and hair follicles. Hair fol-
licles are lined with epidermal keratinocytes and contain multipotent
stem cells [24]. Therefore, if the dermis is only partially injured these ad-
nexal structures can deliver cells that can proliferate, migrate and re-
generate the epidermis. However, the dermis lacks the intrinsic
capability of regeneration and heals by ﬁbrosis and scar formation. Sen-
sory nerves are responsible for mediating pain and itch, control inﬂam-
mation and there is evidence that shows that they may also inﬂuence
the remodeling phase [9]. After skin injury the body starts a remarkable
healing process which often results in complete regeneration.3. Wound healing and keratinocytes
3.1. The role of keratinocytes in wound healing
The skin barrier function can be disrupted by trauma such as a ther-
mal injury. Wound healing usually occurs via four overlapping phases;
haemostasis, inﬂammation, proliferation and remodeling. Normally
this process is sufﬁcient to allow the skin to repair itself after injury.
However, extensive skin loss, as seen in burn victims, requires interven-
tion to allow for tissue restoration. Burn injuries are often caused byheat, however, electricity, radiation, chemicals or friction can also result
in similar injuries clinically [25]. Following thermal injury, a complex
healing processwill start with the involvement of numerous specialized
and interacting cells, molecules and pathways. The cellular response in-
volves macrophages, platelets, ﬁbroblasts, epithelial and endothelial
cells. In addition to the various cellular interactions, proteins and glyco-
proteins such as growth factors, cytokines, chemokines, inhibitors and
their receptors can also inﬂuence healing. Although, burns heal differ-
ently from normal wound healing, the phases of healing remain the
same [26]. Keratinocytes and ﬁbroblasts play an important role in the
proliferative phasewhich is focused on the replacement of the damaged
ECM and restoration of tissue structure and function. Activation of
keratinocytes and ﬁbroblasts by macrophages via cytokine and growth
factor release causes angiogenesis, collagen production, ECM produc-
tion and epithelialisation [27].
3.1.1. Angiogenesis
The restoration of the vascular network is essential as angiogenesis
supports cell activity by providing oxygen and nutrients to the wound
bed. Once endothelial cells are activated by macrophages, they loosen
their cell to cell junctions in order tomigrate. This process aswell as en-
dothelial proliferation is encouraged by a hypoxic and acidotic environ-
ment which is typically found in wounds. Finally, revascularisation
occurs when sprouted vessels organise into capillary networks. Vascu-
larisation consequently neutralizes the hypoxic and acidotic wound en-
vironment and leads to decreased production of angiogenic factors. This
eventually results in reduction of endothelial cell migration and prolif-
eration [8,28].
3.1.2. Epithelialisation
Within hours of injury re-epithelialisation starts with a vital role
being played by keratinocytes. The quantity of epidermal stem cells re-
siding in stem cell niches such as in the hair follicles, sebaceous glands
Fig. 3. Role of keratinocytes in re-epithelialisation. Schematic illustration of a skin injury with keratinocytes as key cells. Keratinocytes are activated via pro-inﬂammatory cytokines and
growth factors released in thewound bed. Once activated, keratinocytes from thewound edges and dermal appendagesmigrate over theprovisionalmatrix andﬁnally close the defect in a
process called epithelization. When the basal layer is spared from injury, basal keratinocytes can support this process by upward migration as occurs in non-injured skin. Activated
keratinocytes communicate with other cell types present in the epidermis. Epithelial cells proliferate and differentiate to achieve a stratiﬁed epithelium with restoration of the barrier
function of the skin. Maturation of the wound continues over a period of several months with ﬁbroblasts remodeling the underlying dermis.
[Source: Britt ter Horst].
22 B. ter Horst et al. / Advanced Drug Delivery Reviews 123 (2018) 18–32and basal layers of the interfollicular epidermis determines the regener-
ative capability of the skin [8,24].
Activated by growth factors released bymacrophages, keratinocytes
migrate to the wound bed and ﬁll the defect (Fig. 3). In order for
keratinocytes to start their migration they undergo phenotypical alter-
ations by loosening of intercellular adhesions, although some desmo-
some contacts are sustained [8]. Furthermore, cells can separate from
the basal layer once hemidesmosomes are disrupted which allows
them tomigrate laterally [8,29].When integrin receptors are expressed,
the keratinocytes ﬂatten and the altered basal keratinocytes migrate
over the granulation tissue to form a monolayer of epithelial cells, but
remain under the non-viable eschar of the burn wound. While moving
they secrete proteolytic enzymes that enable the degradation of provi-
sionalmatrix and promotes further cell migration [30]. After a conﬂuent
sheet of cells covers the wound bed, the cells then divide to form a
multi-layered stratiﬁed epithelium and mature under the inﬂuence of
TGF-β1 and TGF- β2 [31].
Keratinocytes play a vital role in especially the proliferative phase of
burn wound healing leading to epithelialisation and restoration of the
vascular network. For this reason and the possibility of in vitro
keratinocyte culture, keratinocytes are considered an excellent candi-
date for cell transplantation.
3.2. Pathophysiology of burn injury
Major burn injury, deﬁned as approximately 20% of the total body
surface area (TBSA) burned, causes burn shock due to severe haemody-
namic and haematopoietic dysfunction [26] secondary to immediate
evaporative and direct ﬂuid losses [32], extensive loss of proteins, re-
duced colloid oncotic pressure andwound oedema development.With-
out intervention the ﬂuid loss will result in desiccation of deeper tissues
and further cell death leading to an increase in wound depth. A moist
wound bed is necessary for epithelial cell movement and therefore for
successful re-epithelialisation [9]. Furthermore, with disruption of the
barrier function of the skin, microorganisms have easy access and
when entering the microcirculation can cause systemic infection.Presence of these acute systemic responses are related with increased
morbidity and mortality numbers [33,34], especially in the elderly [1].
3.3. Rational for keratinocyte transplantation
Traditional therapy for severe burns is surgical debridement and
autologous skin graft. However, with extensive burn injury healthy
donor site is scarce and alternatives to restore skin function are nec-
essary. When rapid epithelialisation can be achieved the skin barrier
function is restored and this can determine a patient's likelihood of
survival. Clearly, it is important in the treatment of a burn injury to
focus on quick re-epithelialisation. Therefore, development of success-
ful and efﬁcient autologous skin replacement techniques is highly
desirable. Wound closure will not occur without epithelialisation and
epithelialisation will not occur without the presence of keratinocytes
in thewound bed [8]. To achieve faster re-epithelialisation, keratinocyte
transplantation was introduced as part of the burn wound care arsenal
over 30 years ago. However, the original autologous keratinocyte trans-
plantation technique has several disadvantages which has spurred re-
searchers to seek for improvements in cell culture technique, delivery
systems and also the optimisation of the timing of keratinocyte trans-
plantation [35].
4. Cell transplantation technology
4.1. Cell source
Keratinocytes and their progenitor cells can be sourced locally from
stem cell niches in hair follicles. Several stem cell niches are known:
mesenchymal stem cells (MSC) resident in the dermal papilla and
multipotent hair follicle stem cells (HFSC) and melanocyte stem cells
in the superior bulge [36]. HFSCs are essential for normal morphogene-
sis of hair follicles, sebaceous glands and contribute to formation of the
three epithelial cell lines [37]. Progenitor cells also reside in the bone
marrow and could arise from embryonic cell lines [38].
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4.2.1. Historical development of keratinocyte culture
The ﬁrst successful in vitro human keratinocyte expansion, achieved
by Rheinwald and Green in 1975, paved the way towards autologous
cell transplantation in burn care [39]. Keratinocytes were successfully
cultured in the presence of ﬁbroblast feeder cells. However, to prevent
these ﬁbroblasts fromoutgrowing the keratinocyte population, irradiat-
ed murine 3T3 ﬁbroblast feeder cells, which have lost their mitotic abil-
ity but remain metabolically active, were used [39]. Besides the use of
feeder cells, culture media often contains fetal calf serum with growth
factors, hormones and antibiotics [39–41]. Keratinocytes are able to be
grown into colonies and subsequently form a stratiﬁed epithelium and
human keratinocyte stem cells were proven to have an enormous pro-
liferation potential. Subsequently, small cell sheets of two or three
layers of conﬂuent keratinocytes were produced and not long after,
the ﬁrst human transplantation became a reality [42,43].
Keratinocytes cultured for clinical use must have the regenerative
capability to form an effective epidermis after transplantation. It is
thought that in vitro differentiating keratinocytes do not contribute sig-
niﬁcantly to regeneration in vivo [44]. Instead, keratinocyte stem cells
and their transient amplifying cells seem to have excellent regenerative
capacities [45]. Thus, culturing keratinocytes that keep the ability to
produce progeny once transplanted, seems key for successful epidermis
formation following transplantation.
The degree of differentiation in vitro can be controlled by the
method of culture. Fully differentiated keratinocytes (conﬂuent) mul-
tilayers aswell as pre-conﬂuent single cells can be produced and deliv-
ered to thewound bed [16,46]. In a histological comparison of cultured
pre-conﬂuent and uncultured keratinocytes seeded on a collagen-GAG
matrix in a pigmodel, both provided a fully differentiated epidermis in
14 days. A thicker and conﬂuent cell layer, however, was obtained
more rapidly with the cultured cells [47]. The original culture method
has been the subject of much debate, because the murine ﬁbroblast
feeder layers can potentially result in transplantation of animal com-
ponents with the keratinocyte product. Due to the serious risk of ani-
mal-derived disease transmission to human epithelium in the
transplantation process, it is not advised to use undeﬁned xenogeneic
materials in the treatment of patients. Additionally, radioactive irradi-
ation of murine ﬁbroblasts in this technique is accompanied with
higher costs and potential uptake of irradiated DNA via the murine ﬁ-
broblasts into the transplanted keratinocytesmight cause cell destruc-
tion [48].
4.2.2. Progress towards xenobiotic free culture techniques
To limit or exclude the transmission risk, other keratinocyte culture
protocols without feeder cells and limited or no use of xenogeneic
media products have been developed [16,49]. Jubin et al. showed that
human keratinocytes can be successfully expanded in co-culture with
non-irradiated autologous human ﬁbroblasts in Rheinwald and Green
but still required medium supplemented with fetal bovine serum
(FBS) to maintain their proliferative phenotype in vitro [50]. A further
approach to minimise xenogeneic products in culture media was intro-
duced when serum free medium was used for the expansion of
keratinocytes with non-irradiated human ﬁbroblasts on several sub-
strates [49]. However, FBS still had to be used to expand the human ﬁ-
broblasts initially.
Although the culture media are free of serum, often other prod-
ucts used in the culture media still contain animal-derived proteins.
This could be solved by the use of only human material, however the
risk of infection remains and high costs in an already expensive pro-
cess makes this option less favourable. Successful culture of human
keratinocytes in a serum-free and feeder-free culture was demon-
strated in vitro in a skin equivalent model by Coolen et al. With the
addition of collagen type IV, serum substitute and keratinocyte
growth factor (KGF) a differentiated epidermis could be formed[51]. Lamb et al. demonstrated that although keratinocytes grown
in serum-free and feeder-free conditions did show sufﬁcient propa-
gation, these cells were not able to support mature epidermis forma-
tion in an in vitro skin model. However, when re-introduced to a
serum-containing media they then did form a stratiﬁed epidermis.
Moreover, when heat-inactivated serum was used an improved
stratiﬁed epidermis was formed, indicating that serum-products
also contains (heat-sensitive) factors that can inhibit in vitro epider-
mis formation [52].
Lenihan et al. compared three commercially available feeder-free
media systems; CnT-07 medium (CellnTech, Bern, Switzerland),
EDGS (Gibco), S7 (Gibco) with the original Rheinwald and Green
method [39] for expansion of human keratinocytes for clinical usage.
A maximum of 3 weeks culture time (passaged twice) was allowed, as
the ideal transplantation window was considered between 4 and
20 days. They found that all three feeder free culture media supported
keratinocyte growth. However, the only fully xenobiotic free media
(S7) had a low cumulative population doubling time and therefore
did not reach sufﬁcient cell numbers to be considered for clinical
usage at day 21 and was therefore excluded from further analyses [53].
Using feeder free and serum free media is less labour intensive and
beneﬁcial for use in the clinical setting, further research will have to
show whether keratinocytes maintain their proliferative potential in
vivo. Besides elimination of xenobiotic materials from culture media,
the elimination of antibiotics is a further goal to improve keratinocyte
cell expansion for usage in the clinical setting [54].4.2.3. Additions to keratinocyte culture
To further encourage and optimise skin regeneration following
burn injury, improvements have been made to the keratinocyte
transplantation process. These have included the addition of multi-
ple other cell types and growth factors during keratinocyte culture
or transplantation.
The addition of melanocytes in the keratinocyte culturing process
has been proposed to solve the problem of potential irregular pig-
mentation of the post burn scar. Co-culturing of keratinocytes with
melanocytes has been investigated in patients with vitiligo and in
full thickness wound healing in animal models [55–58]. In humans,
more evidence is available for uncultured cell suspensions containing
keratinocytes and melanocytes for the treatment of hypopigmented le-
sions [59–62]. However, these pilot studies are limited by small sample
sizes and lack of controls. Controlled clinical studies are needed to sup-
port the ﬁndings before this technique can be accepted as standard clin-
ical practice.
Cultured epithelial autografts lack a vascular plexus and burn
wounds often have insufﬁcient vascularisation due to the disruption
of the dermal layer. Therefore, approaches to promote angiogenesis
via the addition of autologous or allogenic endothelial cells into
skin grafts have been proposed [63,64]. Also, adipose derived stem
cells (ASCs) have received attention with respect to their potential
to enhance wound healing. Huang et al. seeded human ASCs onto a
dermal acellular skin substitute in vitro to enhance vascularisation.
When transplanted to full thickness wounds in nude mice, an increase
in blood vessel densitywas found twoweeks post transplantation com-
pared to controls [65]. Another approach is to add growth factors like
epidermal growth factor (EGF) [66]. Additionally, co-delivery of cul-
tured keratinocytes with EGF in a ﬁbrin matrix demonstrated improve-
ment of epidermal regeneration in full thickness wounds in a murine
model [67]. Furthermore, Supp et al. genetically modiﬁed keratinocytes
with an overexpression of vascular endothelial growth factor (VEGF) to
stimulate angiogenesis in skin substitutes in animal studies [68,69]. Be-
sides adding factors, modiﬁcations of the 3D structure of skin substi-
tutes to stimulate faster ingrowth of vascular structures have also
been proposed [70]. Of interest from a tissue engineering perspective,
is whether transplanted cells actually survive and function in vivo.
Fig. 4. Burn wound coverage with cultured epithelial autografts applied in sheets. In this example, successful burn wound healing in about 2 weeks was achieved when the sheets were
removed a week after application. a) Deep second degree burn in the back of a 29-year old patient after excision of the burn b) application of cultured keratinocyte sheets c) removal of
sheets 8 days after surgery and d) complete healing 16 days after surgery.
[Reprinted fromBurns Volume 41, Issue 1, Pages 71–79, Cultured autologous keratinocytes in the treatment of large anddeep burns: A retrospective study over 15 years, Celine Auxenfans,
Veronique Menet, Zulma Catherine, Hristo Shipkov, Pierre Lacroix, Marc Bertin-Maghit, Odile Damour, Fabienne Braye, Copyright (2017), with permission from Elsevier.]
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Cell survival of transplanted keratinocytes in vivo is of great interest
for tissue engineering purposes. Vernez et al. evaluated the cell viability
and apoptosis balance in clinical samples taken from cultured epidermal
autografts prior to transplantation [71]. Although, all samples showed
high levels of cell viability and low levels of apoptosis, variable biological
activity of certain parameters between samples of different patientswas
observed. It was suggested that this could impact on therapeutic efﬁca-
cy [71]. In a pigmodel Navarro et al. found no altered cell viability before
and after spraying a suspension of cultured keratinocytes to full thick-
nesswounds [72]. Duncan et al. examined cultured human keratinocyte
proliferation measured with the MTT assay after spray delivery to a de-
epidermalised dermis (DED) in vitro and found no signiﬁcant cell death
or reduced cell proliferation [73]. These studies seem to support that
cells remain viable and maintain proliferative capability after spray
cell delivery to a wound bed.5. Application types of keratinocytes transplantation
5.1. Introduction: grafting of burn wounds
Ambroise Paré (1510–1590 CE) was probably the ﬁrst to describe
the surgical intervention for early excision of burnwounds [74]. Surgical
burn care has progressed tremendously since then and methods which
have nowbecomewell established in burn care include early excision of
burn wounds, the development of autologous and allogenic skin grafts
and the use of skin substitutes [75].
Techniques involving transplantation of healthy human skin to dam-
aged areas are still the gold standard in deep or full thickness burnwounds. However, challenges arise when large areas are affected and
donor sites are scarce. Subsequently, many skin graft expansion tech-
niques have been developed to reduce donor site size, these techniques
include meshing of the graft (maximum expansion ratio of 1:9), modi-
ﬁedmeek technique (expansion ratio of 1:9), epidermal blister grafting
(expansion ratio of 1:1) and several techniques ofmicro grafting such as
epidermal CelluTome™ micro-grafting (expansion ratio: 1:6), or
Xpansion® micro-grafting (maximum expansion ratio: 1:100). Devel-
opers of cellular based techniques claim to deliver even higher expan-
sion rates, such as cultured epithelial sheets (expansion rate 1:1000)
and uncultured cell suspensions (maximum expansion rate 1:100)
[76,77]. However, to the knowledge of the authors no other studies
have been able to support these ﬁndings.
Furthermore, procedures to harvest skin are time consuming, can
lead to longer healing timeswith prolonged hospital stay and can be ac-
companied by donor site complications. Additionally, skin grafts do not
always meet the desired cosmetic outcomes.
Therefore, methods to enhance the results of skin grafting and alter-
natives to it have been subject of much research in the last few decades.
Speciﬁcally, progress towards a permanent epidermal replacement or
its improved regeneration is the main goal of cellular based therapy.
In Fig. 6 different methods of autologous keratinocyte transplantation
are schematically summarized.5.2. Cultured keratinocyte sheets
5.2.1. Cultured autologous keratinocyte sheets
In 1981, O'Connor et al. reported the ﬁrst transplant of cultured au-
tologous keratinocytes to treat a burn injury [43]. Cultured epithelial au-
tografts (CEA) were developed to replace the epidermis and restore the
Fig. 5. Spray delivery of cultured keratinocytes to enhance burn wound healing. In this
example, a mixed depth burn to the abdomen was treated with solely sprayed cultured
keratinocytes (no additional mesh grafting) 27 days after injury. The wound was
considered to have healed completely 10 days after treatment. Unfortunately, long term
outcomes in terms of scar quality were not available for this patient.
[Reprinted from Burns Volume 36, Issue 3, Pages e10–e20, Sprayed cultured autologous
keratinocytes used alone or in combination with meshed autografts to accelerate wound
closure in difﬁcult-to-heal burns patients, S. Elizabeth James, Simon Booth, Baljit Dheansa,
Dawn J. Mann, Michael J. Reid, Rostislav V. Shevchenko, Philip M. Gilbert, Copyright
(2017), with permission from Elsevier.]
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been adapted and introduced to the clinical setting (Fig. 4).
Nowadays, several commercialised bioengineered skin products de-
rived from autologous cells are available. In general, clinicians harvest
autologous skin and the company produces a graftable substrate seeded
with the autologous cells for clinical use in approximately 2 weeks
(Epicel, Genzyme, Cambridge, MA and Laserskin, Fidia, Italy). The
timeframe wherein viability of the grafts can be ascertained (shelf-
life) is 24–48 h. These serviceswill often involve high costs and a certain
waiting time and narrow application timeframe.
In 2007, the FDA approved the use of CEAs for use in patients with
deep dermal or full thickness burns greater than, or equal to 30% TBSA
(Epicel, Genzyme, Cambridge, MA) [43,80,81]. The main advantage of
cultured epithelial autografts is that large areas of the body can be cov-
ered with autologous cells derived from a small biopsy and improve-
ment in the speed of re-epithelialisation has been reported. In terms
of cosmetic results, CEA seems to have better results when compared
to wide mesh autograft in extensive burns [82]. However, several au-
thors who have reviewed the use of cultured epithelial autografts in
burn care have found variability in terms of graft take and cosmetic out-
comes [46,83,84].
A major disadvantage of this technique is the long time-interval
between biopsy and grafting. Although the average culture time has im-
proved from 5 [43] to about 3 weeks [85,86], variability among patientshas been described, especially among different age groups [87]. Follow-
ing burn excision, the wound can be temporary covered with allograft
and/or xenograft dressings for several weeks until CEA is ready. Howev-
er, this is related to a higher risk of wound colonization and infection
[46]. The ideal timing for keratinocyte transplantation is difﬁcult to de-
termine as it is dependent on several factors including hospital facilities
and patient conditions [86,88].
Furthermore, both short and long term clinical limitations such as
the formation of bullae, poor take rates, fragility of the sheets and
wound contractures have been reported [88–90]. These may be due to
the lack of a dermal component that is necessary to support the new
epidermal layer.
The restoration of the dermis is important for the skin to regain
mechanical strength and to facilitate adherence of the new or
transplanted epidermis [36]. Although in one study, an advanced ap-
plication technique with allograft wound bed preparation and com-
bination of CEA with wide meshed autograft seems to improve take
rates up to 84% [91].
Cell culture is an expensive process and the cost/beneﬁt relationship
of this method is heavily debated [92]. Finally, the potential of graft site
malignancy after keratinocyte transplantation has been highlighted [93,
94]. However, the type of malignancy reported, squamous cell carcino-
ma, is also known to occur in burn wounds and scars in the absence of
keratinocyte transplantation [95].
5.2.2. Introduction of dermal substitutes including cultured keratinocytes
With a complete absence of a dermal component, the cultured
keratinocytes are thought to be of limited value in treating full-thick-
ness burns due to the poor quality of the resulting epidermis. Conse-
quently, this has led researchers to optimise the wound bed via the
use of allogenic or artiﬁcial substitutes prior to keratinocyte transplan-
tation. A further approach is to grow or seed the cultured keratinocytes
on a (dermal) substitute to facilitate secure transplantation and im-
prove healing potential [96]. This concept was introduced by
Hansbrough and Boyce in 1989 [97]. Many types of delivery systems
have since followed, and have been extensively discussed in the litera-
ture throughout the years [98–100].
Limitations in keratinocyte cell culture methods and transplantation
have impeded the widespread use of this technique in the clinical set-
ting. The use of single-cell suspension was introduced predominantly
to shorten the culture time.
5.3. Autologous keratinocyte transplantation in suspension
To overcome the main negative features of epidermal sheets which
are the long culture times and poor cell adhesion to thewound bed, de-
livery of cells in suspension form has been investigated.
While epidermal sheets contain cultured conﬂuent cells that are
passed the phase of exponential growth, cell suspension delivery
systems can be designed to contain pre-conﬂuent cells. Ideally,
these cells are harvested or passaged when reaching a 70–80% cover-
age of culture dishes to ensure their proliferative capability and
avoid conﬂuence, hence the term pre- or sub conﬂuent cells. When
a sufﬁcient cell number is reached (after approximately 2 weeks of
culture), the cells are detached and suspended in a saline solution for
clinical use. As differentiation in vitro is not desirable, keratinocytes in
a pre-conﬂuent suspension form is often preferred for transplantation
(Fig. 5).
Nowadays, several commercially available spray cell delivery prod-
ucts are used clinically to enhance burn wound healing. These tech-
niques can be categorised by the type and level of conﬂuence of the
transplanted cells.
5.3.1. Pre-conﬂuent keratinocytes suspension
The use of pre-conﬂuent cells can shorten culturing time and facili-
tate more rapidly available cellular grafts, which in theory is likely to
Fig. 6.Methods of autologous keratinocyte transplantation to burn wounds. In patients with burn injury keratinocytes can be isolated from a small skin biopsy as illustrated above. The
autologous keratinocytes can be cultured and delivered to the wound bed of the patient by several methods. First to be developed was a sheet of cultured epithelial cells, thereafter a
single cell suspension applied to the wound by dripping from a syringe and latest development is application of cultured or uncultured cells in single-suspension with a spray device.
[Source: Britt ter Horst].
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pital stay [101,102]. A commercial suspension consisting of autologous
pre-conﬂuent keratinocytes has been available since 2007 for aerosol
delivery. Hartman et al. treated 19 patients with deep dermal face and
neck burns with a spray apparatus with an estimated spray pressure
of 8.2 mm Hg, which seems to be a surprisingly low delivery pressure
using autologous cultured epithelial cells of 80–90% conﬂuence at the
end of passage 0 [103].
An alternative commercially available cell spray system is
Kerahealtm, which was developed by MCTT, Korea. This system uti-
lises an autologous non-differentiated pre-conﬂuent keratinocyte
suspension, which is sprayed to the burn wound followed by ﬁbrin
spray application. The Kerahealtm methodology is similar to conven-
tional CEA and requires 2–3 weeks of culture time, but the cells are
provided in a suspension instead of sheet. To date, two single centre
retrospective studies have evaluated the clinical outcomes of the
sprayed cell suspension in combination with wide meshed skin
grafts in a total of 39 (6 patients who died or were lost to follow up
were excluded from follow up analyses) patients with severe
burns. Graft take rate two weeks after application is surprisingly dif-
ferent between the studies, but after 8 weeks the take rates are both
above 90%. A follow up of 1–2 years was achieved in both studies
with a Vancouver scar scale (VSS) assessment. Scar evaluation
12 months after surgery was lower in Lee et al. with an average VSS
of 3 compared to an average VSS of 5 in Yim et al. [101,102].
Various developers have introduced adjustments to the technique in
terms of the application device, cell detachment process, conﬂuency of
transplanted cell and application setting in order to meet clinical needs.
5.3.2. Uncultured keratinocytes suspension
A further approach is the use of uncultured autologous cells for di-
rect application onto burn wounds without pre-processing in a tissueculture lab. In a single procedure, a small piece (2 × 2 cm) of skin is har-
vested by the surgeon and then placed in an enzymatic solution follow-
ed by manual scraping of the epidermal layer, the skin specimen is
placed in a buffer solution and subsequently ﬁltered before use. The
company provides a kit which allows the clinical team to process the
cells in a single treatment session without the need for a lab technician
or transport of the cells elsewhere [83,104]. The use of an uncultured
mixture of autologous epidermal cells (keratinocytes,melanocytes, der-
mal ﬁbroblasts and Langerhans cells)was introduced to clinical practice
in 2005 as a standardized spray device under the name ReCell (Avita
Medical Europe Ltd., Melbourne, UK).
The purported beneﬁts of this system are the elimination of lengthy
culture times and the delivery of a mixture of autologous epidermal
cells.
Since its introduction, several studies have demonstrated promising
outcomes with the use of ReCell for acute burn wounds or in the treat-
ment of hypopigmentation. These studies ranged from case reports to
larger comparative studies [105,60,106–109]. Although most papers
have shown promising results, the potential value of spray cell trans-
plantation in burns is difﬁcult to evaluate due to the heterogeneity of
the studies in terms of clinical outcomes explored, patient population,
wound characteristics, type of treatment and study design [99]. Gerlach
et al. used a similar approach with direct application of an uncultured
autologous epidermal suspension on thewound bed using a ﬁne needle
spray in a single treatment session. Although, a small number of pa-
tients was treated and results were not compared to controls [110,
111]. The question arises whether a large wound area can be covered
by the harvest of cells without expansion from a small skin specimen.
In an in vitro study an expansion ratio of over 1:100 was calculated
for uncultured cells sprayed with a density of 104 cells/cm2 for an esti-
mated surface coverage [112]. However, there is no other literature to
support the claimed expansion rate.
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by the National Institute for Health and Clinical Excellence (NICE) that
studies evaluating spray delivery of uncultured cells need to include at
least: the time to 95% healing of the burn wound, length of hospital
stay, scar assessment, physical function and cosmetic appearance of
the burned area and compare these results with the current standard
of care [69]. To date, randomized controlled clinical trials and non-com-
mercial studies investigating effectiveness compared to conventional
treatment are lacking. Challenges arise in consistent assessment for
burn wound healing as objective non-invasive assessment tools have
not yet been incorporated widely in routine burn care and might not
be superior to visual expert assessment [26]. Therefore, researchers
rely on subjective clinical assessments for acute burn wound healing
and late outcomes in terms of scarring [113].
5.3.3. Allogeneic neonatal keratinocytes suspension
Several research groups have explored the possibility of the trans-
plantation of fetal allogenic cells with the purpose of stimulating regen-
eration of residual cells in the wound. Neonatal foreskin derived
allogenic cells have low immunogenic properties which is preferred in
tissue transplantation. This work has resulted in the creation of skin
substitutes that have been seeded with allogenic cells such as Apligraf
(Organogenesis, Canton, MA) and Orcel (Ortec International, Inc., New
York, New York).
Similar to the developments in autologous cells delivery, allogenic
cell suspensions have also been investigated as an alternative method
of cell delivery. A cell suspension, code named HP802–47, which con-
tains allogenic neonatal non-proliferating human keratinocytes and ﬁ-
broblasts in thrombin was developed for the use in chronic wounds.
Multi-centre randomized controlled phase IIa and IIb studies were con-
ducted and have demonstrated promising outcomes in wound closure
of venous leg ulcers [114–118]. Subsequently, a double blinded Phase
III study followed in North America and Europe comparing wound clo-
sure after HP802-247 treatment or placebo in venous leg ulcers. Howev-
er, the study was unexpectedly halted in the preliminary stages due to
disappointing results [119]. To the knowledge of the authors, no clinical
studies have been conducted for the treatment of burn wounds with
HP802-247.
5.3.4. Other clinical studies using cell sprays
Delivery of mesenchymal stem cell (MSC) to (burn) wounds is con-
sidered very promising due their capacity to differentiate into multiple
lineages and potential beneﬁcial effects on the immune response [54].
However, only few clinical studies investigated the use of mesenchymal
stem cells to treat burn wounds have been performed so far [120–122].
Ueda conducted a pilot study of 10 patients treated with cultured epi-
thelial autograft (CMEA) delivered to deep dermal burn wounds with-
out adverse events and a healing time of approximately 12 days
(range 7–14 days) [123].
Iman et al. compared spray delivery versus intradermal injection of
autologous cultured keratinocyte-melanocyte suspension to treat
hypopigmented burn scars in a total of 28 patients. Although patients
might show a beneﬁcial result with pigmentation, no statistical differ-
ence in type of application was found [59].
Cell transplantation techniques have changed signiﬁcantly after the
introduction of different cell-carriers and various forms of cell spray
techniques. Nevertheless, some shortcomings of the suspension appli-
cation technique have yet to be addressed.
For example, spraying on an uneven wound bed that often also
occurs on a curved body contour, can result in uneven spreading of
the of the cell suspension or dripping off the wound bed [46,124]. A
potentially useful development of keratinocyte transplantation is to
improve the method of delivery in order to optimise cell delivery to
the designated area and stimulate cell adherence to the wound
bed. More recently, cell transplantation exploiting hydrogel carriers
have gain interest among researchers. In the past decadebiomaterials to mediate cell delivery and accommodate cells in a
3Dmicroenvironment have been investigated. A plethora of synthet-
ic and natural polymers which may form hydrogels have been stud-
ied as potential cell delivery vehicles due to their ability to integrate
with healthy tissue.
5.4. Hydrogels
Hydrogels are deﬁned as polymer networks with the ability to swell
and absorbwaterwithin their structure. Due to their hydrophilic nature
and ﬂexibility they are very similar mechanically to human soft-tissue.
Both natural and synthetic hydrogels could be considered for tissue en-
gineering. Natural hydrogels beneﬁt from high biological afﬁnity and
are often easily degradable, but the risk of infection transmission and
difﬁculties with puriﬁcation has increased the popularity of synthetic
hydrogels.
[125,126] Biopolymer gels can be formed out of polysaccharides or
proteins. For example, polysaccharides obtained from plants (gum aca-
cia, guar gum, starch, psyllium [127]), seaweeds (alginate, agarose, car-
rageenans), micro-organisms (dextran, gellan gum) or animal derived
(chitosan, chitin) (hyaluronic acid) and proteins gained from animal
or human tissue (collagen, ﬁbrin, gelatin, elastin) or animal products
(silk sericin, silk ﬁbroin) [128].
5.4.1. Hydrogels in burn care
Hydrogels currently available for patient care have been reviewed by
many clinicians, but a skin substitute that is able to achieve complete
skin regeneration has not yet been reported [79,129-131]. However,
hydrogels play a promising role in the development of next generation
skin substitutes in burn care and are often used as wound dressings
[132,133], regenerative scaffolds or delivery devices for cells and thera-
peutic e.g. drugs, growth factors etc. Hydrogels have several characteris-
tics to promote skin healing such as the ability to absorb and release
water, which is useful in regulating burn wound exudate. Furthermore,
the architecture of hydrogels can be modiﬁed to mimic the body's own
extracellular matrix and their tunable mechanical properties can pro-
vide customised elasticity and ﬂexibility [125] and make them suitable
candidates for skin regeneration [66,134-139].
5.4.1.1. Chitosan. Chitosan is a hydrophilic, non-toxic polysaccharide de-
rived from de-acetylated chitin, obtained from crustaceans or fungi
[140]. Due to its numerous advantageous characteristics such as the
ability to encourage haemostasis, the ability to be modiﬁed so that it
can be degraded by human enzymes and availability of a variety of for-
mulation forms [141], chitosan hydrogels have been widely used in
many biomedical applications. Topical forms of chitosan are used as
wound healing stimulating dressings, for haemostasis [142-143] and
speciﬁcally for use in the treatment of burn wounds [144-145].
Furthermore, the positive inﬂuence of chitosan on keratinocyte pro-
liferation and adhesion has been described previously [146] and chito-
san as a bio-active polymer is suggested as a promising candidate for
tissue regeneration [147.
5.4.1.2. Alginate. Alginate is a negatively charged polysaccharide derived
from the cell walls of brown algae (seaweed) and has hydrophilic prop-
erties. Besides its widespread use in the food and paper-printing indus-
try, it has gained much popularity as a biomaterial due to its non-
immunogenicity, low cost, and simple gelation method. Alginate is
FDA approved for medical applications and is commercially available
as alginate based dressings such as Kaltostat® which are widely used
in burn treatment [9,148] Alginate dressings are also commonly used
for the coverage of donor sites post-skin harvest and has also been suc-
cessful in the treatment of paediatric burn patients [149].
5.4.1.3. Fibrin. Fibrin is a protein which can be derived from human or
animal blood. It can naturally form a gel and acts as a haemostatic
28 B. ter Horst et al. / Advanced Drug Delivery Reviews 123 (2018) 18–32agent in the body after tissue injury. For this reason,ﬁbrin has been used
as a sealant (ﬁbrin glue) in the medical ﬁeld [150]. For wound healing,
ﬁbrin sealants and gels have been used for the delivery of several cell
types such as ﬁbroblasts [151-152], mesenchymal stem cells [121] and
keratinocytes [153-155]. Speciﬁcally, in keratinocyte spray delivery, ad-
ditional ﬁbrin sealant seems beneﬁcial for adhesion of the suspension to
the (artiﬁcial) wound bed [40,124,156]. In contrast, Currie et al. per-
formed a histological and immunohistological analysis and did not
show a difference when adding ﬁbrin glue to a keratinocyte spray deliv-
ery system in terms of epithelialisation [157].
Furthermore, ﬁbrin has also been explored for keratinocyte trans-
plantation in combination with a dermal substitute. For example, en-
capsulated keratinocytes seeded in alloderm [158], keratinocytes
seeded on a ﬁbrin based dermal matrix containing ﬁbroblasts [153,
159] or as a glue to enhance adhesion of human dermis [160] or Integra
[161]. More recently, angiogenesis stimulating factors have been added
to ﬁbrin scaffolds to improve regeneration of ischemic tissue [162].
5.4.1.4. Collagen. Collagen is the most abundant protein in the human
body, it is the main structural protein of the extracellular matrix and
has a key role in wound healing [163]. Therefore, many tissue
engineered collagen based products have been developed. In 1981,
Burke and Yannas developed an artiﬁcial dermal replacement based
on collagen, which has eventually led to the production of the
commercialised dermal substitute Integra [164]. In the same decade,
Hansbrough et al. used a collagen-glycosaminoglycan scaffold with at-
tached cultured autologous keratinocytes and ﬁbroblasts in burn
wound treatment [97]. Since then, collagen matrices in different forms
have been investigated thoroughly inwound healing; as (a)cellular der-
mal replacements [163-168] or as a bilayered skin substitutes such as
Orcel [166], Transcyte [169], Apligraft [170], Integra [171] and
Matriderm [63]. Also, collagen hydrogels have been developed for tissue
regeneration [64] with autologous cells incorporated to improve burn
wound healing [139]. Although widely investigated and used in clinical
practice, collagenmatrices and hydrogels have a fast degradation when
applied to human tissuewhich can have anundesirable effect. However,
the rapid degradation of collagen-based biomaterials can be stabilized
through chemical cross-linking [172].
Examples of other hydrogels used for cell delivery in wound healing
or speciﬁcally burn care are gelatin [173], hyaluronic acid [81,174], silk
sericin [70,175] and dextran [66,176].
All the above mentioned hydrogels have been successfully translat-
ed to clinical practice and some are part of the standard burn wound
treatment arsenal. Hydrogels have advanced burn care as part of tissue
engineered skin substitutes, incorporated in dressings, topical creams or
as sprayable substance.
6. Methods of spray deposition
6.1. Spray parameters and cell viability
Cell transplantation can be achieved by several techniques. In this
chapter the focus lies on cell transplantation to the tissue via aerosol
or spray delivery.
Sprayed cells are expected to bedamaged at time of impact to the re-
ceiving surface. Following impact, the cell membrane can elongate and
deform. Cell rupture and subsequently cell death can occur in largely
overstretched cell membranes [177]. More precisely, cells can tolerate
a cell membrane area stretch of up to 5% before it becomes detrimental
to cell survival. Cell elongation, deformation and subsequent cell surviv-
al depends onmany variables such as target surface characteristics, vis-
cosity of the transporting ﬂuid/media and velocity of the delivered cell
containing droplet, nozzle distance and diameter.
Veazey et al. investigated the cell viability of xenogeneic 70% conﬂu-
enceﬁbroblasts immediately after aerosol deliverywith anairbrush sys-
tem and their growth behaviour in a culture model [178]. The airbrushsystem used could be adjusted for different nozzle diameters (312,
494, 746 μm) and air pressure at delivery (ranging from 41 kPa to
124 kPa). It was found that cell viability directly measured post aerosol
delivery signiﬁcantly decreased with higher pressure and smaller noz-
zle diameter. For cell proliferation studies, only the highest pressure
with smallest nozzle diameter combination showed a delayed popula-
tion doubling time and the time to reach conﬂuence was doubled [178].
In another in vitro studywith 80% conﬂuence neonatal dermal rat ﬁ-
broblasts an analytical model was proposed to describe the impact of
several spray parameters in a droplet-based spray application to the
cell viability. Stiffness of the tissue surface, high cell-viscosity and cell-
velocity had a negative inﬂuence on cell viability post spray impact,
whereas a larger cell-containing droplet diameter had a positive effect
on cell viability. The latter was explained as a cushioning effect of the
droplet to the surface protecting the cell within the droplet [179].
In other words, cell viability is expected to be highest in large and
low-viscosity single cell-containing droplets sprayed with low-velocity
onto a soft tissue surface.
Wounds would serve as a soft receiving surface for cell transplanta-
tion and can be expected to be highly viscous when hydrogels are used.
Hence, tailored spray devices, with pressures and nozzle diameters op-
timized for cell survival can play an important role in improving cell
delivery.6.2. Spray systems
Spray systems are beingwidely used inmany industries. Surprising-
ly little research has focused on the inﬂuence of the type of aerosol de-
vice on mammalian cell survival after transplantation.6.2.1. Low and high pressure spray nozzle
Fredriksson et al. evaluated 7 different application techniques for
cell transplantation on cell viability and proliferation in an in vitro
study. Based on current clinical practice they included commercially
available spray systems: spray nozzle systems such as the Harvest
SK/S Spray Applicator Kit®, high and low pressure Tissomat applica-
tor in combination with a Duploject™ spray nozzle, a Duploject™
spray nozzle without additional pressure control and two non-
spray systems: pipetting and paintbrushing. This study showed an
approximate 50% drop in viable cell count immediately after trans-
plantation when using a high pressure device (200 kPa) and a fur-
ther decline to nearly 40% viable cell count after 2 weeks of
culturing, which was comparable to the paintbrush [180]. In contrast,
Harkin et al. measured a 20% higher post aerosol delivery cell survival
with similar pressures [156]. The immediate cell survival is comparable
with other studies utilising low pressure delivery methods/systems
[178]. Although no statistically signiﬁcant differences were displayed,
the poorest cell viability after 2weekswas seen in the high pressure de-
vice and paintbrush [180]. Fredriksson et al. hypothesised that an addi-
tional application of ﬁbrin sealant might improve cell survival.
Furthermore, the authors emphasized the importance of measuring
the proliferation capacity of cells post aerosolisation, since a large differ-
ence was seen in their data among the different devices. Interestingly,
the delivery pressure and nozzle diameter of clinically used manual
cell spray devices is unclear and might impact on cell viability and pro-
liferation capacity.
Aerosol delivery with handheld airbrush systems with adjustable
air pressure supply have also been previously investigated and stud-
ies have demonstrated consistent acceptable cell viability of above
80% with low delivery pressure (below 69 kPa) [171,178]. According
to Veazey et al., this system should also be compatible with alginate-,
gellan, hyaluronic and hyaluronate-based hydrogel cell carriers [68].
However, to date, there is no published data to support this
statement.
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Liquid atomizers or nebulizers originally designed for aerosol drug
delivery to the trachea have also been explored for cell delivery. In
burns, inhalation injury can occur with damage to the trachea and
drug- or cell delivery could be used to improve the healing of these in-
jured areas. Sosnowski et al. investigated the use of 5 different atom-
izers for cell delivery to the trachea in terms of cell viability. However,
a droplet size below 20 μmwas found to be incompatible for ﬁbroblast
encapsulation and 3 nebulizer devices had to be excluded. The nasal at-
omizer (NA) andMicrosprayer Aerosolizer (MSA) had above 90% viable
cells post spraying, but the viable cell count in the NA group declined to
65% 48h after spraying, indicating that it was amore destructive aerosol
technique [181].
All spray cell delivery techniques have been investigated in vitro or
rodent studies, which has led to the development of commercial spray
devices that are now available in clinical practice for burn wound
treatment.
7. Potential therapeutic applications
7.1. Future approaches keratinocyte transplantation
Several reviews in the last decade have discussed the future implica-
tions of skin tissue engineering and/or speciﬁcally keratinocyte cell
transplantation in the treatment of burns [35,36,54,131,182].
Larger burnwounds often requiremesh grafting. Autologous epider-
mal cell transplantation can complement mesh grafting by stimulating
rapid epithelialization, which is highly desirable to improve patient's
chance of survival and eventually improve scarring. Burns speciﬁc clin-
ical studies investigating keratinocyte transplantation are available, but
due to heterogeneity of the studies and different outcome parameters
the evidence remains low. Comparative trials with standardized out-
comes and ideally randomized treatment for available cell transplanta-
tion techniques are required.
Due to the disadvantages of CEA sheets, future research is focused on
optimizing keratinocyte proliferation by transplantation of pre- or sub
conﬂuence cells. Further improvement of keratinocyte culture method
in terms of culture time, reducing infection risk and elimination of xe-
nobiotic products and also antibiotics needs to be further investigated.
Graft attachment in keratinocyte transplantation remains an im-
portant focus for research. Boyce and Supp developed a cultured skin
substitute containing cultured human keratinocytes and ﬁbroblasts
attached to a collagen-glycosaminoglycan matrix which seems to
form a basement membrane at the dermal-epidermal junction in
vitro [183]. Importance of basement membrane formation and
rapid epithelialisation has to be taken into account in novel cell
spray or carrier delivery methods [183,184].
7.2. Future spray cell delivery systems for burns wound care
Spray cell delivery to burnwounds can overcome themajor issues of
conventional grafting techniques by reducing donor site and enhance
fast re-epithelialisation. The available delivery systems can be improved
by optimizing spray features to aim for high cell viability and prolifera-
tion. This should be tailored according to cell type and receiver surface.
Spray features to optimise might be: air delivery pressure, nozzle de-
signs, carrier type and depending on technique of delivery, cell contain-
ing droplet size [178,179,181 ]. Further research should take into
account the importance of preventing cell damage, since this could re-
ﬂect poor proliferation [178,180]. Hydrogels could potentially serve as
amechanical protection for the cells during transplantation and provide
structural support once transplanted. Although in vitro studies have
shown good short term cell survival post aerosol delivery, clinical stud-
ies have not been able to show similar results as yet. The challenge for
researchers is to develop a feasible spray delivery system with accept-
able cell viability and proliferation which can be translated to clinicalstudies. Also, current clinical cell spray devices could potentially beneﬁt
from these optimized features.
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